{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:59:07Z","timestamp":1790258347077,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NCI, Cairo University"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","translationalres.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.trsl.2014.07.009","type":"journal-article","created":{"date-parts":[[2014,8,7]],"date-time":"2014-08-07T18:02:00Z","timestamp":1407434520000},"page":"396-406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data"],"prefix":"10.1016","volume":"165","author":[{"given":"Abeer A.","family":"Bahnassy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Fawzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El-Wakil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel-Rahman N.","family":"Zekri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Abdel-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Sheta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2014.07.009_bib1","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1399-3046.2012.01704.x","article-title":"Current concepts in pediatric liver tumors","volume":"16","author":"Emre","year":"2012","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.trsl.2014.07.009_bib2","series-title":"Cancer pathology registry and time trend analysis","first-page":"20","author":"Mokhtar","year":"2007"},{"key":"10.1016\/j.trsl.2014.07.009_bib3","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/aje\/kwj104","article-title":"Maternal and infant birth characteristics and hepatoblastoma","volume":"163","author":"McLaughlin","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.trsl.2014.07.009_bib4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1055\/s-2004-815784","article-title":"Mesenchymal hamartomas of\u00a0the liver may be associated with increased serum alpha foetoprotein concentrations and mimic hepatoblastomas","volume":"14","author":"Boman","year":"2004","journal-title":"Eur J Pediatr Surg"},{"key":"10.1016\/j.trsl.2014.07.009_bib5","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1200\/JCO.2000.18.14.2665","article-title":"Randomized comparison of cisplatin\/vincristine\/fluorouracil and cisplatin\/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group","volume":"14","author":"Ortega","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2014.07.009_bib6","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1200\/JCO.2009.22.4857","article-title":"Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study","volume":"28","author":"Zsiros","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2014.07.009_bib7","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.ejca.2005.02.035","article-title":"The emerging family of hepatoblastoma tumours: from ontogenesis to oncogenesis","volume":"41","author":"Zimmermann","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.trsl.2014.07.009_bib8","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1756-9966-30-96","article-title":"HGF\/c-Met related activation of \u03b2-catenin in hepatoblastoma","volume":"12","author":"Purcell","year":"2011","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.trsl.2014.07.009_bib9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.med.58.062105.204854","article-title":"Cancer stem cells: models and concepts","volume":"58","author":"Dalerba","year":"2007","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.trsl.2014.07.009_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/mt.2008.254","article-title":"Cancer stem cell-directed therapies: recent data from the laboratory and clinic","volume":"17","author":"Park","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.trsl.2014.07.009_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00383-010-2719-x","article-title":"Isolation and identification of cancer stem cells from a side population of a human hepatoblastoma cell line, HuH-6 clone-5","volume":"27","author":"Hayashi","year":"2011","journal-title":"Pediatr Surg Int"},{"key":"10.1016\/j.trsl.2014.07.009_bib12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.molmed.2008.08.003","article-title":"Cancer stem cell markers in common cancers\u2014therapeutic implications","volume":"14","author":"Klonisch","year":"2008","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.trsl.2014.07.009_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.yexmp.2010.05.005","article-title":"Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma","volume":"89","author":"Lingala","year":"2010","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.trsl.2014.07.009_bib14","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/jemt.22237","article-title":"Detection of CD133 (prominin-1) in a human hepatoblastoma cell line (HuH-6 clone 5)","volume":"76","author":"Akita","year":"2013","journal-title":"Microsc Res Tech"},{"key":"10.1016\/j.trsl.2014.07.009_bib15","doi-asserted-by":"crossref","first-page":"9550","DOI":"10.1200\/jco.2010.28.15_suppl.9550","article-title":"Sorafenib, gamma-secretase inhibitor, and bortezomib as potential therapeutic agents for hepatoblastoma","volume":"28","author":"Sanchez-Diaz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trsl.2014.07.009_bib16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccr.2008.11.002","article-title":"Hepatic stem-like phenotype and interplay of Wnt\/beta-catenin and Myc signaling in aggressive childhood liver cancer","volume":"14","author":"Cairo","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trsl.2014.07.009_bib17","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/modpathol.2013.80","article-title":"Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium","volume":"27","author":"L\u00f3pez-Terrada","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.trsl.2014.07.009_bib18","unstructured":"National Cancer Institute at the National Institutes of Health. http:\/\/www.cancer.gov\/clinicaltrials\/search\/view?version=healthprofessional&cdrid=654889. Accessed October 8,\u00a02013."},{"key":"10.1016\/j.trsl.2014.07.009_bib19","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by comparative CT method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat Protoc"},{"key":"10.1016\/j.trsl.2014.07.009_bib20","doi-asserted-by":"crossref","first-page":"e19506","DOI":"10.1371\/journal.pone.0019506","article-title":"CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres","volume":"6","author":"Walter","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2014.07.009_bib21","doi-asserted-by":"crossref","first-page":"24706","DOI":"10.3390\/ijms141224706","article-title":"Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastoma","volume":"14","author":"Alisi","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.trsl.2014.07.009_bib22","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1478-3231.2009.02126.x","article-title":"Hepatic progenitor cells in liver cancers from Asian children","volume":"30","author":"Ward","year":"2010","journal-title":"Liver Int"},{"key":"10.1016\/j.trsl.2014.07.009_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2001-1326-2-3","article-title":"Mechanisms of chemoresistance in cancer stem cells","volume":"2","author":"Abdullah","year":"2013","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.trsl.2014.07.009_bib24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/08880010590964192","article-title":"Effects of P-glycoprotein modulation on the chemotherapy of xenotransplanted human hepatoblastoma","volume":"22","author":"Warmann","year":"2005","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.trsl.2014.07.009_bib25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc1590","article-title":"Tumour stem cells and drug resistance","volume":"5","author":"Dean","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.trsl.2014.07.009_bib26","first-page":"447","article-title":"Development of a drug resistance model for hepatoblastoma","volume":"38","author":"Eicher","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1016\/j.trsl.2014.07.009_bib27","first-page":"1081","article-title":"Cancer stem cell as a potential therapeutic target in hepatocellular carcinoma","volume":"12","author":"Pang","year":"2012","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.trsl.2014.07.009_bib28","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1158\/1078-0432.CCR-09-2933","article-title":"The difficulty of targeting cancer stem cell niches","volume":"16","author":"LaBarge","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trsl.2014.07.009_bib29","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ejca.2005.02.004","article-title":"Guidelines for surgical treatment of hepatoblastoma in the modern era: recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL)","volume":"41","author":"Czauderna","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.trsl.2014.07.009_bib30","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jpeds.2004.09.011","article-title":"The current management of\u00a0hepatoblastoma. A combination of chemotherapy, conventional resection, and liver transplantation","volume":"146","author":"Tiao","year":"2005","journal-title":"J Pediatr"},{"key":"10.1016\/j.trsl.2014.07.009_bib31","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1034\/j.1600-6143.2002.20607.x","article-title":"Treatment of unresectable hepatoblastoma with liver transplantation in the pediatric population","volume":"2","author":"Ernesto","year":"2002","journal-title":"Am J Transplant"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524414002722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524414002722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T03:23:32Z","timestamp":1538364212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524414002722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S1931524414002722"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2014.07.009","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2014.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}